EUVIMEDEUVIMED entdecken
Crossref

Exosomal miR-130a-3p confers cisplatin resistance in esophageal cancer by regulating ferroptosis via the suppression of METTL14-mediated m6A RNA methylation of FSP1

Hu Han, Yan Li, Zhiyi Lin, Xiaoping Ma, Wukui Huang, Cengceng Lu, Rongyan Ma, Rui Han

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2024.113804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Hu Han und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Shihezi University, Shihezi 832008, China. Electronic address: hanhu2022@shzu.edu.cn. Hauptthemen laut MEDLINE: Cisplatin, MicroRNAs, Esophageal Neoplasms, Exosomes. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 62 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Exosomal microRNA (miRNA)s have been proven to affect recipient cell chemoresistance in several cancers. This research attempted to uncover the role of exosomal miRNA and the regulatory mechanism in cisplatin resistance of esophageal cancer (EC). Cisplatin-resistant EC cells (KYSE-150-CisR and TE-1-CisR) were established by the parental cells (KYSE-150 and TE-1) treated with a gradual increase of cisplatin concentration. Exosomes from both cisplatin-resistant EC cells and the parental one were obtained with ultracentrifugation (CisR-exo and CisS-exo), and identified by transmission electron microscopy and nanoparticle tracking analysis. The effect of CisR-exo on the cisplatin resistance of EC was assessed by in vitro (and in vivo functional experiments.Intracellular reactive oxygen species and iron were determined by the corresponding kits. The m6A dot blot assay and methylated RIP-qPCR was conducted to analyze the m6A modification level. Dual-luciferase reporter assay was performed to confirm the intermolecular interaction. Increased levels of miR-130a-3p were observed in both KYSE-150CisR and TE-1CisR cells, as well as their derived CisR-exos when compared with the parental cells and CisS-exos. Exosomal miR-130a-3p from cisplatin-resistant EC cells conferred cisplatin resistance to EC in vitro and in vivo, which might be mediated by the suppression of ferroptosis. Mechanically, KYSE-150CisR derived exosomal miR-130a-3p interacted with METTL14 to inhibit FSP1 (a ferroptosis suppressor) m6A modification of recipient cells. Overexpressing METTL14 restrained the cisplatin resistance disseminated by CisR-exos in KYSE-150 cells. Cisplatin-resistant EC cell-isolated exosomal miR-130a-3p suppressed the m6A modification of FSP1 to modulate ferroptosis, enhancing cisplatin resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinMicroRNAsEsophageal NeoplasmsExosomesMethyltransferasesAntineoplastic AgentsHumansDrug Resistance, NeoplasmFerroptosisAnimalsCell Line, TumorMiceMethylationMice, NudeMice, Inbred BALB CGene Expression Regulation, NeoplasticRNA Methylation

Stichwörter der Autor:innen

CisplatinEsophageal cancerExosomeFerroptosisMETTL14

Substanzen

CisplatinMicroRNAsMethyltransferasesMETTL14 protein, humanMIRN130 microRNA, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Oncology, The First Affiliated Hospital of Shihezi University, Shihezi 832008, China. Electronic address: hanhu2022@shzu.edu.cn.
  • Medical Department, The First Affiliated Hospital of Shihezi University, Shihezi 832008, China. Electronic address: 779506214@qq.com.
  • Department of Oncology, The First Affiliated Hospital of Shihezi University, Shihezi 832008, China. Electronic address: 82427518@qq.com.
  • Department of Oncology, The First Affiliated Hospital of Shihezi University, Shihezi 832008, China. Electronic address: 496833175@qq.com.
  • Department of Interventional Diagnosis and Treatment, Affiliated Cancer Hospital, Xinjiang Medical University, Urumqi 830054, China. Electronic address: 15909911798@163.com.
  • Department of Oncology, The First Affiliated Hospital of Shihezi University, Shihezi 832008, China. Electronic address: ccym0123@163.com.

Zitieren

APA

Han, H., Li, Y., Lin, Z., Ma, X., Huang, W., Lu, C., Ma, R., & Han, R. (2025). Exosomal miR-130a-3p confers cisplatin resistance in esophageal cancer by regulating ferroptosis via the suppression of METTL14-mediated m6A RNA methylation of FSP1. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113804

Vancouver

Han H, Li Y, Lin Z, Ma X, Huang W, Lu C, et al. Exosomal miR-130a-3p confers cisplatin resistance in esophageal cancer by regulating ferroptosis via the suppression of METTL14-mediated m6A RNA methylation of FSP1. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2024.113804

BibTeX
@article{Han2025,
  author = {Han, Hu and Li, Yan and Lin, Zhiyi and Ma, Xiaoping and Huang, Wukui and Lu, Cengceng and Ma, Rongyan and Han, Rui},
  title = {Exosomal miR-130a-3p confers cisplatin resistance in esophageal cancer by regulating ferroptosis via the suppression of METTL14-mediated m6A RNA methylation of FSP1},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2024.113804}
}
Kostenlos starten →